Kornimate/medical-research-clean huggingface dataset:
a non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (rcc) in the uk

Conditions: Advanced Renal Cell Carcinoma

Summary: clinical experience with cabozantinib is limited in the uk and ireland and there is anecdotal evidence of there being variability between clinicians in terms of where cabozantinib is used in the treatment pathway. the present study aims to collate and report the experiences of a sample of national health service (nhs) trusts that enrolled patients onto the managed access programme. the study will describe the positioning of cabozantinib in the treatment pathway, associated clinical outcomes and characteristics of patients with advanced rcc receiving cabozantinib in this early clinical experience setting. the results will provide valuable information for collective learning on how to prescribe and manage cabozantinib and its optimal positioning in the patient pathway. overall, the findings will contribute to a better understanding of how best to manage patients with advanced rcc in routine practice.


Eligibility criteria:
inclusion criteria: * a diagnosis of advanced rcc * prescribed cabozantinib as part of the managed access programme (map) (alive or deceased at study data collection) * aged ≥18 years at start of cabozantinib treatment. exclusion criteria: * decline or lack the capacity to consent for researcher access to their medical records (if living) * hospital medical records are unavailable for review
rct ks-sa versur ks-ba in diabetic patients

Conditions: Dental Implant; Diabetes

Summary: the aim of this randomized controlled trial is to evaluate whether is better to place ks osstem implants with ba or sa surface placed in patients with type 2 diabetes, and to compare clinical and radiographic data.


Eligibility criteria:
inclusion criteria: * - patients of at least 18 years old able to sign an informed consent. * patients with at least a single tooth loss in the maxilla or mandible. patient will provide only one site for the research. implant sites must allow the placement of implants of at least 3.5 mm (upper laterals and lower incisors); 4 mm (central incisors, canines, and premolars) or 4.5 (molars) mm of diameter and at least 7 mm of length. * smokers will be included and categorized into: 1) non smokers; 2) moderate smokers (smoking up to 10 cigarettes/day); 3) heavy smokers (smoking more than 11 cigarettes/day). * patients with a plaque index (pi) of less than, or equal to 25% at the time of surgery. * in case of post-extractive sites, they must have been healing for at least 4 months before being treated in the study. * patients with controlled type 2 diabetes mellitus with a duration of at least 1 years of disease evaluation and baseline glycated hemoglobin a1c (hba1c) values between 7.5% and 12% at the time of implant placement will be included. exclusion criteria: * general contraindications to implant surgery (except for type two diabetes in test group). * patients irradiated in the head and neck area. * immunosuppressed or immunocompromised patients (except for type two diabetes in test group). * patients treated or under treatment with intravenous amino-bisphosphonates. * patients with untreated periodontitis. * patients with poor oral hygiene and motivation. * previous guided bone reconstruction at the intended implant sites. * uncontrolled diabetes (except for type two diabetes in test group). * pregnancy or nursing. * substance abuser. * psychiatric problems or unrealistic expectations. * lack of opposite occluding dentition in the area intended for implant placement. * patients with infection and or inflammation in the area intended for implant placement. * patients participating in other studies, if the present protocol cannot be properly adhered to. * patients referred only for implant placement and cannot be followed ant the treating centre. * patients unable to be followed for 5 years.

Keywords: dental implant diabetics patients implant-abutment connection
vit d to treat asthma in children: a randomized, double-blind, placebo-controlled trial

Conditions: Asthma

Summary: the purpose of this study is to determine whether vitamin d supplements can improve asthma control in children with moderate to severe asthma

the proposed interventional study will clarify the role of vitamin d in preventing asthma exacerbations and in achieving better chronic asthma control in children with moderate to severe asthma.

Eligibility criteria:
inclusion criteria: * physician diagnosed asthmatics and they should fulfill at least two of the following three criteria: * a minimum of three clinic visits for acute asthma within 1 year * two or more asthma-related hospital admissions within 1 year, or * steroid dependency, as defined by either 6 months of oral or 1 year of inhaled corticosteroid use * age: 6-14 years old. the age group of 6 to 14 years old was chosen for two reasons: 1. diagnostic accuracy of asthma is better in this age group as non-specific wheezers less than 6 years of age could be excluded. 2. child should be able to use a peak flow meter and perform spirometry tests. * a positive specific ige or a positive skin prick test for at least one airborne allergen. exclusion criteria: * children with mild intermittent and mild persistent asthma. * asthmatic children who are currently on immunotherapy or anti ige. * asthmatic children with concomitant other medical problems. * children who are younger than 6 yrs or older than 14 yrs. * children with history of early life injury to airways like premature birth (\< 36 weeks) or home use of oxygen. * children with vitamin d deficiency. since these children may be randomized to the control group, they will be excluded for ethical reasons.

Keywords: asthma asthma therapy randomized controlled trial children
ursodeoxycholic acid in c. difficile infection

Conditions: Clostridioides Difficile Infection

Summary: the primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid


Eligibility criteria:
inclusion criteria: * completion of a course of antibiotic treatment for c. difficile infection within the previous 7 days exclusion criteria: * • pregnant or breast-feeding * gall bladder inflammation * frequent episodes of biliary colic * occlusion of the common bile duct or cystic duct * active small intestinal inflammation * previous resection of distal small intestine * treatment with bile salt binding agents, ciclosporin or ciprofloxacin * diarrhoea (from any cause) at study initiation * hypersensitivity to bile acids or any excipient of the formulation * life expectancy less than 6 months
patient satisfaction in post-lasik patients with presbyopia-correcting iols vs. post-lasik patients with monofocal iols

Conditions: Patient Satisfaction

Summary: compare functional visual outcomes and patient satisfaction of post-lasik patients having received presbyopia-correcting iols versus post-lasik patients having received monofocal iols


Eligibility criteria:
inclusion criteria: * post-lasik * post cataract surgery * implantation of zlb00, zxr or zxt, zcb00, or ao60 intraocular lenses * spherical values greater than ± 0.50 and/or cylinder magnitude greater than 0.75d exclusion criteria: * any vision-limiting problems (e.g., corneal, retinal, infection) which could potentially limit their post-operative visual potential * any newly acquired ocular condition or pathology (e.g., armd, epiretinal membrane, chronic dry eye, irregular astigmatism, diabetic retinopathy) * max sphere no greater than ± 0.50d and cylinder less than and/or equal to 0.75d

Keywords: post-lasik presbyopia-correcting iol monofocal iol
the effect of dairy and non-dairy breakfasts on satiety and post-meal glycemia in healthy older adults

Conditions: Diabetes; Obesity

Summary: this study investigates the effects of dairy breakfasts (2% cow's milk, 2% greek yogurt, cheese) and a non-dairy breakfast (soy beverage) on satiety and post-meal blood glucose. each participant will receive every treatment in this crossover design study.

regular consumption of dairy is associated with better body composition and lower incidences of type 2 diabetes and obesity. this may be due to dairy's ability to increase satiety and decrease post-prandial glycemia. however, most clinical studies have only investigated isolated dairy proteins (whey and casein) and the effects of whole dairy products, consumed as part of a meal, remain unclear. additionally, the effect of dairy type and form remain to be further investigated. therefore, this study will test the effects of dairy products when consumed with a high glycemic index breakfast on satiety and post-prandial glycemia. thirty healthy older males and females (60-70 years, bmi 18.5-30.0 kg/m2) will be recruited for the randomized, unblinded, crossover study. participants will fast overnight, and at baseline will consume 1) 2% milk (250 ml), 2) soy beverage (250 ml), 3) plain 2% greek yogurt (175 g), 4) cheddar cheese (30 g), or 5) water (250 ml - control). treatments will be consumed along with 2 pieces of white toast with strawberry jam, except for the water control which will be consumed alone. all breakfast meals will be isocaloric and water will be given with the yogurt (75 ml) and cheese (220 ml) to compensate for fluid content. at 0 (baseline), 15, 30, 45, 60, 90, 120, 150, 180, (pre-meal period) and 210 minutes (post-meal period) blood will be collected for glucose analysis and subjective appetite ratings completed. insulin will be analyzed every 30 minutes. between 180-200 minutes, an ad libitum lunch will be provided to assess food intake.

Eligibility criteria:
inclusion criteria: * healthy bmi (18.5-30.0 kg/m2) * regular breakfast consumers * menopausal for at least 1 year (females) exclusion criteria: * smoking * diabetes * fasting blood glucose equal to or higher than 6.0 mmol/l * cardiovascular disease * medication affecting appetite or metabolism * trying to lose or gain weight through a diet or exercise regime * lactose intolerance or allergies to study foods * score equal to or higher than 11 on eating habits questionnaire

Keywords: dairy post-prandial glycemia satiety food intake insulin milk greek yogurt cheese soy beverage
portal vein thrombosis in neonate with umbilical catheter

Conditions: Portal Vein Thrombosis

Summary: the aim of this study is to identify incidence of portal vein thrombosis after umbilical catheter and to identify the risk factor of this condition ,location of pvt and prognosis of pvt.

the use of umbilical venous catheters (uvcs) in the neonatal period may be associated with severe complications including the occurrence of portal vein thrombosis (pvt )(1) the placement of an umbilical venous catheter (uvc) is a common procedure in neonatology and has multiple clinical indications driven by the need for quick and secure access for medication administration. umbilical venous catheters allow quick access for administering drugs, blood products, fluids and parenteral nutrition to acutely ill neonates; however, they are have many complications. the most common complication is nosocomial sepsis ranging from 3% to 16%, followed by thromboembolism and catheter malposition in the heart, great vessels or portal system(2,3) the diagnosis is made by abdominal doppler ultrasonography . in the cases with portal venous thrombosis, the location, extent, and size of the thrombus were recorded occlusive was defined by hyperechogenic thrombus replacing the entire lumen and no-flow in color doppler or partial which defined by non-occlusive hyperechogenic intraluminal thrombus and persistent stream in color doppler.(4) a prospective observational study of newborns, who were admitted to the neonatal intensive care unit assiut university children's hospital ,neonates who had undergo uvc for any cause between 10/2023 to 9/2024 will enroll in these study with serial ultrasonography of the uvc to determine the incidence and location of thrombi in infants after umbilical catheterization. all cases included in the study will be evaluated by birth weight, gender, gestational age, type of catheter, duration of catheter use, types of infused fluids, and location of the catheter tips (uvc), ultrasound examinations of the liver and spleen including color doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the department of pediatric diagnostic imaging by a radiologist after removal of the catheter and in case of pvt subsequent serial u/s will preformed until clot resolution.

Eligibility criteria:
inclusion criteria: * the study population: all neonates with uvc, who will admitted to the neonatal intensive care unit assiut university children's hospital had undergo uvc for any cause between 10/2023 to 9/2024 limited to diagnosis established in neonates \<28-day chronological age. exclusion criteria: * neonate who has pvt but not had uvc before .
keratoconus, corneal diseases and transplant registry

Conditions: Corneal Diseases; Keratoconus; Corneal Ulcer; Corneal Trauma; Corneal Dystrophies

Summary: the cornea is the clear layer in front of the iris and pupil. it protects the iris and lens and helps focus light on the retina. corneal diseases are serious conditions that can cause clouding, distortion, scarring and eventually blindness. there are several types of corneal disease with keratoconus being one of the most prominent. keratoconus is a weakening and thinning of the central cornea. this thinking causes the cornea to develop a cone-shaped deformity leading to vison loss. keratoconus is usually bilateral affecting people between 10 and 25. this project aims to collect data on patient suffering with corneal diseases and the treatments they receive, including corneal transplantation, over a period of time during routine clinical practice. a clinical registry such as this can be a very useful tool to provide a real-world view of clinical practice, patient outcomes, safety, and comparative effectiveness. •methods: data will be collected from the medical records of patients who have suffered from corneal disease and have undergone treatment in the ophthalmology department of the chu montpellier. a standardized set of data will be collected for all patients. this will include, demographic and social date such as lifestyle and occupation, current and past pathologies and treatment received. this is data that is already collected as part of routine clinical practice. this will be an ongoing registry with the aim of collecting the maximum data possible. the more patients that are entered and the longer the follow up for each patient, the more valuable the data will become. •discussion: the aim of this registry to help create a better understanding of variations in treatment and outcomes; to examine factors that influence prognosis; to describe treatment patterns, including appropriateness and effectiveness of treatment and disparities in the delivery of care; to monitor safety and harm and to measure quality of care. in the long term the data collected in the registry may serve as a basis for the development of evidence-based clinical management guidelines to help clinicians deliver the most appropriate treatment for corneal diseases in the safest and most efficient manner.


Eligibility criteria:
inclusion criteria: * suffering from a corneal disease * undergoing treatment in the ophthalmology department of the chu montpellier * has been presented with an opt-out consent form exclusion criteria: * expressed a desire to not be included in the study

Keywords: pseudophakic and aphakic bullous keratopathy ophthalmology cornea keratoconus cornea transplant corneal dystrophies crosslinking
use of titanium plate in rhinoplasty in patients with cleft lip and palate : aesthetic and functional impact.

Conditions: Cleft Lip; Cleft Palate

Summary: the patients in this study are all born with a cleft lip and palate. they underwent several interventions in childhood to take care of it. professor gleizal offered them a secondary rhinoplasty aimed at normalizing the appearance of their nose. in this malformative and multioperated context, typical nasal deformities affect the tip of the nose, which appears to be sagging and asymmetrical. scarred soft tissues exert an important retractile force against which conventional rhinoplasty techniques often remain insufficient. the use of columellar struts makes it possible to give again projection to the tip of the nose but when this strut is made from cartilage or bone, it is absorbed with the time. moreover, these interventions require a remote removal of the site of interest (costal cartilage, tibial crest, calvaria) which generates additional morbidity. the investigators propose an alternative using a synthetic graft of titanium. this material has been used for many years for its excellent biocompatibility and trauma resistance. 28 patients were able to benefit from this technique between march 1, 2016 and march 1, 2018. the investigators wish to evaluate the aesthetic and functional results from the patient's point of view by submitting them to one validated rhinoplasty questionnaire after the end of the patient's inclusion.


Eligibility criteria:
inclusion criteria: * patient over 12 years * patients with cleft lip and palate operated by pr gleizal of a secondary rhinoplasty using a titanium columellar strut * between january 1, 2016 and march 1, 2018 * patient not having opposed their participation exclusion criteria: * patient not mastering the french language * patient participating in interventional research
effect of il17 inhibitor in comparison with anti-tnf in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: ankylosing spondylitis (as) is a chronic, inflammatory autoimmune disease characterized by axial bone inflammation. the main clinical manifestations include back pain and progressive spinal rigidity, as well as inflammation of the hips, shoulders, and peripheral joints. also, extra-articular manifestations, such as psoriasis, uveitis, and inflammatory bowel disease (ibd). indicators of inflammation such as erythrocyte sedimentation rate (esr) and creactive protein (crp), which are typically elevated in as patients, particularly when peripheral joints are involved, these tests ultimately do not reflect the disease process and have limited sensitivity and specificity. disease activity in as has been measured by the bath ankylosing spondylitis disease activity index (basdai), which includes only patient-reported measures. the assessment of spondyloarthritis international society (asas) developed a new as disease activity score (asdas) that combines patient-reported assessments with erythrocyte sedimentation rate (esr) or c-reactive protein (crp). although platelets play important functions in hemostasis and thrombosis, their functions in controlling immunity and inflammation have drawn more attention recently. platelets are known to have a key role in controlling inflammatory processes in a variety of pathological states. overactivated platelets can induce inflammation, which in turn can increase the risk of the development of atherosclerosis, thrombosis, and cardiovascular disorders. inflammatory diseases, including inflammatory bowel disease (ibd), have platelets play a crucial role in their development. the first-line recommended treatment for active as is nsaids. tumor necrosis factor (tnf) inhibitors have completely changed the therapy options for patients who have not improved despite receiving standard nsaid treatment. tnf inhibitors can, however, cause tolerability problems in certain patients or inadequate responses in others, and their effectiveness may gradually diminish. interleukin (il)-17 inhibitors are among the new therapeutic alternatives that are currently accessible for these individuals.


Eligibility criteria:
inclusion criteria: * patients fulfill the assessment in spondyloarthritis international society (asas) classification criteria for axial spondyloarthritis. * patients with disease duration more than 6 months. * patients who failed conventional treatment and on bdmards (il17 or anti-tnf-α). * age above 16 years old. * patient cooperative and can answer questions. * patients who are able and willing to give written informed consent. exclusion criteria: * other rheumatologic or collagen diseases. * age below 16 years and above 60 years. * uncooperative patients. * patient not able and willing to give written informed consent. * patient with other causes of platelet dysfunction, count irregularity.

Keywords: ankylosing spondylitis anti-tnf il17 inhibitor il17 platelet piology
effects of web-based adolescent health promotion program in hearing impaired adolescents

Conditions: Health Promotion

Summary: our research is to evaluate the effect and applicability of the adolescent health promotion program, which includes multiple behavioral interventions, on physical activity, nutrition and mental health of hearing impaired adolescents living in the community.

purpose of the research; to evaluate the effect and applicability of the web-based adolescent health promotion program, which includes multiple health behavior initiatives, on physical activity, nutrition, and stress management of hearing impaired adolescents in making healthy choices, assuming their own health responsibilities and acquiring healthy lifestyle behaviors. materials and methods; the research is a full experimental study with pretest-posttest control group, repeated measurement design, random groups. research sample; a total of 70 hearing-impaired adolescents aged 12-18, studying at abdurrahman gazi sağlar primary school, van special education vocational high school and duyus special education and rehabilitation center affiliated to the ministry of national education in the city center of van. the data of the research; "sociodemographic characteristics information form", "body mass index (bmi)", "adolescent nutrition information scale", "adolescent physical activity information scale", "adolescent lifestyle scale", "adolescent healthy lifestyle choices scale", "renewed child" anxiety and depression scale", "daily food consumption form", "beverage consumption form", "pedometer" were collected. in the study; descriptive statistics will be evaluated with mean, standard deviation, percentage and frequency analysis. comparisons between groups will be analyzed using pearson's chi-square, student's t-test, mann whitney-u test, kruskal wallis test, analysis of variance and cohen's d effect size. the results of this study; * physical variables: body mass index (bmi) and weight * behavioral variables: weekly average number of steps and change, fruit and vegetable consumption amount, amount of water consumed, amount of sugary and acidic beverages consumed, "adolescent lifestyle" scale score average, "adolescent" lifestyle choices scale score average, * cognitive variables: "adolescent nutrition knowledge" scale mean score, "adolescent physical activity knowledge" scale mean score, "regenerated child anxiety and depression" scale mean score will be evaluated.

Eligibility criteria:
inclusion criteria: * hearing impairment, * in the 12-18 age group, * ability to access communication tools such as computers, tablets and smartphones and use the internet with these tools, * able to communicate in visual, sign language and written, * does not have a physical condition or disease that may prevent exercise, * volunteer to participate in the research, * permitted to participate in the research by their parents. exclusion criteria: * who want to withdraw from the research

Keywords: hearing impaired adolescent health health promotion web-based asge- fabes